JP2022541938A - 選択的エストロゲン受容体分解剤 - Google Patents
選択的エストロゲン受容体分解剤 Download PDFInfo
- Publication number
- JP2022541938A JP2022541938A JP2022504655A JP2022504655A JP2022541938A JP 2022541938 A JP2022541938 A JP 2022541938A JP 2022504655 A JP2022504655 A JP 2022504655A JP 2022504655 A JP2022504655 A JP 2022504655A JP 2022541938 A JP2022541938 A JP 2022541938A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- cancer
- less
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029554 | 2019-07-22 | ||
| IN201921029554 | 2019-07-22 | ||
| PCT/IB2020/056914 WO2021014386A1 (en) | 2019-07-22 | 2020-07-22 | Selective estrogen receptor degrader |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541938A true JP2022541938A (ja) | 2022-09-28 |
| JP2022541938A5 JP2022541938A5 (cg-RX-API-DMAC7.html) | 2023-08-02 |
Family
ID=71842730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504655A Pending JP2022541938A (ja) | 2019-07-22 | 2020-07-22 | 選択的エストロゲン受容体分解剤 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) * | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| US12391667B2 (en) | 2019-07-22 | 2025-08-19 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
| PE20241731A1 (es) * | 2022-02-01 | 2024-08-19 | Lilly Co Eli | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno |
| CN119176799B (zh) * | 2024-09-19 | 2025-10-03 | 晨伫(杭州)生物科技有限责任公司 | 色烯衍生物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014205136A1 (en) * | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| WO2017072792A1 (en) * | 2015-10-27 | 2017-05-04 | Sun Pharma Advanced Research Company Limited | Novel heterocyclic antiestrogens |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| DE69023906T2 (de) | 1990-08-09 | 1996-04-11 | Council Scient Ind Res | Benzopyrane und Verfahren zu deren Herstellung. |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
| US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
| AU8102398A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | (dl)-2,3-diaryl-2h-1-benzopyrans |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EP2791132A4 (en) | 2011-12-14 | 2015-08-05 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| BR112014014767A2 (pt) | 2011-12-16 | 2017-06-13 | Olema Pharmaceuticals Inc | novos compostos de benzopirano, composições e usos dos mesmos |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| CN103879283B (zh) * | 2014-03-10 | 2019-01-15 | 浙江吉利汽车研究院有限公司 | 一种电动车辆 |
| CN107406433A (zh) * | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的2,3‑二苯基色烯的衍生物 |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
-
2020
- 2020-07-22 US US16/936,022 patent/US11014915B2/en active Active
- 2020-07-22 JP JP2022504655A patent/JP2022541938A/ja active Pending
- 2020-07-22 BR BR112022001285A patent/BR112022001285A2/pt not_active IP Right Cessation
- 2020-07-22 AU AU2020317099A patent/AU2020317099A1/en not_active Abandoned
- 2020-07-22 CA CA3148592A patent/CA3148592A1/en active Pending
- 2020-07-22 CN CN202080053315.6A patent/CN114302879A/zh active Pending
- 2020-07-22 WO PCT/IB2020/056914 patent/WO2021014386A1/en not_active Ceased
- 2020-07-22 MX MX2022001013A patent/MX2022001013A/es unknown
- 2020-07-22 EP EP20747136.8A patent/EP4003525A1/en not_active Withdrawn
- 2020-07-22 KR KR1020227005904A patent/KR20220046586A/ko not_active Ceased
- 2020-07-22 PE PE2022000135A patent/PE20221588A1/es unknown
- 2020-07-22 PH PH1/2022/550182A patent/PH12022550182A1/en unknown
-
2021
- 2021-05-05 US US17/308,501 patent/US20210261534A1/en not_active Abandoned
-
2022
- 2022-01-22 CL CL2022000156A patent/CL2022000156A1/es unknown
- 2022-01-23 IL IL290036A patent/IL290036A/en unknown
- 2022-01-25 ZA ZA2022/01157A patent/ZA202201157B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014205136A1 (en) * | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| WO2017072792A1 (en) * | 2015-10-27 | 2017-05-04 | Sun Pharma Advanced Research Company Limited | Novel heterocyclic antiestrogens |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202201157B (en) | 2023-07-26 |
| CA3148592A1 (en) | 2021-01-28 |
| BR112022001285A2 (pt) | 2022-03-22 |
| WO2021014386A1 (en) | 2021-01-28 |
| PE20221588A1 (es) | 2022-10-10 |
| MX2022001013A (es) | 2022-02-22 |
| US20210261534A1 (en) | 2021-08-26 |
| KR20220046586A (ko) | 2022-04-14 |
| US20210024504A1 (en) | 2021-01-28 |
| IL290036A (en) | 2022-03-01 |
| CN114302879A (zh) | 2022-04-08 |
| AU2020317099A1 (en) | 2022-02-24 |
| PH12022550182A1 (en) | 2022-11-14 |
| US11014915B2 (en) | 2021-05-25 |
| EP4003525A1 (en) | 2022-06-01 |
| CL2022000156A1 (es) | 2022-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11014915B2 (en) | Selective estrogen receptor degrader | |
| JP7277424B2 (ja) | テトラヒドロ-1H-ピリド[3,4-b]インドール抗エストロゲン薬物 | |
| CN1181077A (zh) | 苯并吡喃类化合物及其使用方法 | |
| CN105451735B (zh) | 氮杂环丁烷雌激素受体调节剂和其用途 | |
| CN107406433A (zh) | 用于治疗癌症的2,3‑二苯基色烯的衍生物 | |
| CN108143728A (zh) | 选择性雄激素受体调节剂在治疗乳癌中的用途 | |
| US20230348441A1 (en) | Bicyclic compound that acts as crbn protein regulator | |
| JP2023126540A5 (cg-RX-API-DMAC7.html) | ||
| KR20210018460A (ko) | 선택적 에스트로겐 수용체 분해제 | |
| TW201710253A (zh) | 抗雌激素化合物 | |
| JP2025523065A (ja) | アゾポドフィロトキシン誘導体su056のエナンチオマー | |
| US20080085930A1 (en) | Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate | |
| JP2008510020A (ja) | アナストロゾール中間体の不純物及びその使用 | |
| JP2008510020A6 (ja) | アナストロゾール中間体の不純物及びその使用 | |
| EP4003996B1 (en) | Estrogen receptor-modulating compounds | |
| WO2004031125A1 (ja) | スピロ化合物、それを含有する医薬組成物及び該化合物の中間体 | |
| JP5054882B2 (ja) | テトラヒドロベンズフルオレン誘導体 | |
| RU2855858C2 (ru) | ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА | |
| WO2025255358A1 (en) | Solid forms of posiphen d-tartrate and processes of preparation thereof | |
| HK40056233A (en) | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs | |
| CN115819407A (zh) | 一种Ensitrelvir类似物及其制备方法和抗新冠用途 | |
| HK40075686A (en) | Estrogen receptor-modulating compounds | |
| EA048255B1 (ru) | Режим дозирования для лечения рака | |
| HK1247195A1 (en) | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer | |
| HK1214532B (en) | Estrogen receptor modulator and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230720 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230720 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230724 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240827 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250218 |